Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rx Promotion Remains Potential Political Liability, Attorneys Warn

Mar 05 2001

• By The Pink Sheet

Related Content

AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA

Sep 11 2000

Celgene Thalomid Promotions For Off-Label Cancer Use Draw FDA Warning

May 01 2000

Celebrex GI Safety, Warfarin Claims Over Vioxx Need Corrective Letter - FDA

Feb 12 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window